Regencell Bioscience Holdings Ltd (RGC) stock
RGCNasdaqMedicinal Chemicals & Botanical Products
$4.55−0.17 (-3.60%)
Close on Nov 17, 2026Market cap $2.26BP/E –Yield –
Regencell Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was $1.30M, up 37.0% from the year before. The highest annual figure on record is $2.51M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $1.30M | +37.0% |
| FY2025 | Jun 30, 2025 | $948.29K | -11.1% |
| FY2024 | Jun 30, 2024 | $1.07M | -32.6% |
| FY2023 | Jun 30, 2023 | $1.58M | -37.0% |
| FY2022 | Jun 30, 2022 | $2.51M | +473.1% |
| FY2021 | Jun 30, 2021 | $438.32K | +13.5% |
| FY2020 | Jun 30, 2020 | $386.23K | +69.2% |
| FY2019 | Jun 30, 2019 | $228.22K | – |
See a number that looks wrong?